Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)

CompletedOBSERVATIONAL
Enrollment

1,555

Participants

Timeline

Start Date

June 13, 2022

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions
Alzheimer DiseaseMild Cognitive ImpairmentMemory LossMemory DisordersMemory Impairment
Interventions
OTHER

Prescreener database

Identify and characterize participants with reported memory complaints and/or cognitive impairment to determine the probability of randomization into a therapeutic AD clinical trial.

Trial Locations (19)

22031

Re:Cognition Health, Fairfax

30030

iResearch, Decatur

32159

Charter Research, Lady Lake

32751

ClinCloud, LLC, Maitland

K2 Medical Research, Maitland

32789

Conquest Research, Winter Park

32792

Charter Research, Winter Park

32940

ClinCloud, LLC, Viera

32952

Merritt Island Medical Research, Merritt Island

33180

Visionary Investigator's Network, Aventura

33407

Premiere Research Institute at Palm Beach Neurology, West Palm Beach

33462

JEM Research Institute, Lake Worth

34471

Renstar Medical Research, Ocala

48334

Quest Research Institute, Farmington Hills

73106

IPS Research, Oklahoma City

78229

Clinical Trials of Texas, San Antonio

92103

Pacific Research Network, San Diego

92705

Syrentis Clinical Research, Santa Ana

V1V 1Z9

OCT Research, Kelowna

All Listed Sponsors
lead

Global Alzheimer's Platform Foundation

OTHER